ENZ

Enzo Biochem, Inc. [ENZ] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ENZ Stock Summary

Top 10 Correlated ETFs

ENZ


Top 10 Correlated Stocks

ENZ


In the News

01:18 28 Mar 2024 ENZ

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.

04:05 28 Mar 2024 ENZ

Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders

FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.

06:00 28 Mar 2024 ENZ

Top Sectors to Explore for Penny Stocks to Buy

Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

06:00 28 Mar 2024 ENZ

Penny Stock Psychology: Developing a Winning Mindset

Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:46 28 Mar 2024 ENZ

Why Is Enzo Biochem (ENZ) Stock Up 72% Today?

Enzo Biochem (NYSE: ENZ ) stock is rocketing higher on Friday after the company agreed to an asset sale with Labcorp (NYSE: LH ). That asset sale has Enzo Biochem agreeing to divest its Clinical Laboratory division to Labcorp.

09:49 28 Mar 2024 ENZ

Enzo Biochem, Inc. (ENZ) Q1 2023 Earnings Call Transcript

Enzo Biochem, Inc. (NYSE:ENZ ) Q1 2023 Earnings Conference Call December 13, 2022 8:30 AM ET Company Participants Unidentified Company Representative - IR Hamid Erfanian - CEO Patricia Eckert - Interim CFO Conference Call Participants Operator Greetings and welcome to the Enzo Biochem, Incorporated First Quarter 2023 Earnings Call. At this all participants are in a listen-only mode.

06:18 28 Mar 2024 ENZ

Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th

Conference Call and Webcast Scheduled for December 13 th , 8:30 AM ET

06:04 28 Mar 2024 ENZ

Enzo Biochem, Inc. Announces Date of Annual Shareholders' Meeting

NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders' Meeting will be held on January 31, 2023.  Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely.

11:31 28 Mar 2024 ENZ

Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th

Conference Call and Webcast Scheduled for October 1 4 , 202 2 , 8 : 3 0 a m ET

10:17 28 Mar 2024 ENZ

Enzo Biochem, Inc. (ENZ) CEO Hamid Erfanian on Q3 2022 Results - Earnings Call Transcript

Enzo Biochem, Inc. (NYSE:ENZ ) Q3 2022 Earnings Conference Call June 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Hamid Erfanian - Chief Executive Officer David Bench - Chief Financial Officer Conference Call Participants J. P. Sullivan - Potomac Capital Operator Greetings and welcome to the Enzo Biochem Third Quarter 2022 Financial Results and Business Update.

ENZ Financial details

Company Rating
Sell
Market Cap
64.54M
Income
33.02M
Revenue
12.81M
Book val./share
1.4
Cash/share
1.29
Dividend
-
Dividend %
-
Employees
179
Optionable
No
Shortable
Yes
Earnings
12 Jun 2024
P/E
2.78
Forward P/E
-
PEG
-0.57
P/S
3.46
P/B
0.95
P/C
0.98
P/FCF
-1.62
Quick Ratio
2.54
Current Ratio
3.05
Debt / Equity
0.06
LT Debt / Equity
0
-
-
EPS (TTM)
-0.24
EPS next Y
-
EPS next Q
1.58
EPS this Y
61.7%
EPS next Y
-
EPS next 5Y
375.89%
EPS last 5Y
-18.32%
Revenue last 5Y
-17.48%
Revenue Q/Q
9.57%
EPS Q/Q
-53.38%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
22.29%
Inst Trans
0.58%
ROA
24%
ROE
50%
ROC
-0.19%
Gross Margin
-89%
Oper. Margin
-73%
Profit Margin
123%
Payout
-
Shs Outstand
51.23M
Shs Float
35.39M
-
-
-
-
Target Price
-
52W Range
1.16-2.74
52W High
-36.5%
52W Low
+27%
RSI
50
Rel Volume
0.41
Avg Volume
101.29K
Volume
41.47K
Perf Week
4.1%
Perf Month
-5.93%
Perf Quarter
-10.56%
Perf Half Y
-7.97%
-
-
-
-
Beta
0.753
-
-
Volatility
0.02%, 0.05%
Prev Close
0%
Price
1.27
Change
1.6%

ENZ Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-07-31

Metric History 2019-07-312020-07-312021-07-312022-07-31 2023-07-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.711.62.442.210.63
Net income per share
-2.09-0.710.07-0.470.41
Operating cash flow per share
0.1-0.360.01-0.34-0.75
Free cash flow per share
-0.07-0.41-0.08-0.41-0.81
Cash per share
1.271.010.90.451.68
Book value per share
1.821.231.421.121.6
Tangible book value per share
1.641.061.260.821.6
Share holders equity per share
1.821.231.421.121.6
Interest debt per share
0.110.690.470.430.14
Market cap
185.14M113.13M157.1M117.19M72.61M
Enterprise value
129.6M98.05M166.25M116.18M-2.76M
P/E ratio
-1.87-3.3445.87-5.193.58
Price to sales ratio
2.281.491.331.092.34
POCF ratio
38.52-6.59405.95-7.06-1.96
PFCF ratio
-55.77-5.85-38.8-5.84-1.83
P/B Ratio
2.151.942.292.150.93
PTB ratio
2.151.942.292.150.93
EV to sales
1.61.291.411.09-0.09
Enterprise value over EBITDA
1.6-6.5213.27-10.60.23
EV to operating cash flow
26.97-5.71429.6-70.07
EV to free cash flow
-39.04-5.07-41.06-5.790.07
Earnings yield
-0.53-0.30.02-0.190.28
Free cash flow yield
-0.02-0.17-0.03-0.17-0.55
Debt to equity
0.060.560.330.380.09
Debt to assets
0.050.290.20.210.06
Net debt to EBITDA
-0.6810.730.096.22
Current ratio
5.092.12.712.212.46
Interest coverage
000-97.530
Income quality
1.930.60.050.91-1.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.550.650.380.50.88
Research and developement to revenue
0.040.060.030.040.13
Intangibles to total assets
0.080.070.070.080
Capex to operating cash flow
-1.690.13-11.460.210.07
Capex to revenue
-0.1-0.03-0.04-0.03-0.09
Capex to depreciation
-2.68-0.78-1.67-1.23-1.03
Stock based compensation to revenue
0.020.020.010.020.1
Graham number
9.234.441.513.433.86
ROIC
-33.91-0.250.04-0.21-0.41
Return on tangible assets
-1.01-0.320.03-0.260.17
Graham Net
1.090.090.26-0.070.95
Working capital
65.44M35.96M44.51M29.8M58.47M
Tangible asset value
77.54M50.39M60.89M47.01M78.46M
Net current asset value
60.84M14.61M25.48M12.96M55.04M
Invested capital
0.060.560.330.380.09
Average receivables
11.94M9.94M9.67M10.86M8.16M
Average payables
8.39M7.88M8.31M8.32M6.04M
Average inventory
7.56M7.81M10.22M14.03M11.68M
Days sales outstanding
48.2943.8931.6239.2656.5
Days payables outstanding
45.7259.446.2247.766.93
Days of inventory on hand
49.4254.3871.9886.4148.64
Receivables turnover
7.568.3211.549.36.46
Payables turnover
7.986.157.97.655.45
Inventory turnover
7.396.715.074.222.46
ROE
-1.15-0.580.05-0.410.26
Capex per share
-0.17-0.05-0.09-0.07-0.06

Quarterly Fundamentals Overview

Last date of statement is 2024-01-31 for Q2

Metric History 2023-01-312023-04-302023-07-312023-10-31 2024-01-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.340.33-0.40.160.17
Net income per share
-0.22-0.31.18-0.13-0.06
Operating cash flow per share
-0.13-0.1-0.35-0.27-0.18
Free cash flow per share
-0.15-0.12-0.36-0.27-0.18
Cash per share
0.10.051.691.381.29
Book value per share
0.670.381.611.481.4
Tangible book value per share
0.370.081.611.481.4
Share holders equity per share
0.670.381.611.481.4
Interest debt per share
0.380.61-0.030.140.09
Market cap
65.3M121.98M72.08M67.25M63.62M
Enterprise value
78.85M141.27M-3.3M5.07M5.56M
P/E ratio
-1.53-2.070.31-2.54-5.2
Price to sales ratio
47.57-3.678.617.44
POCF ratio
-10.54-24.14-4.23-5.03-7.12
PFCF ratio
-9.24-21.32-4.09-4.93-7.1
P/B Ratio
1.996.440.920.910.9
PTB ratio
1.996.440.920.910.9
EV to sales
4.838.770.170.650.65
Enterprise value over EBITDA
-6.66-20.86-0.26-2.94-4.8
EV to operating cash flow
-12.72-27.950.19-0.38-0.62
EV to free cash flow
-11.16-24.70.19-0.37-0.62
Earnings yield
-0.16-0.120.8-0.1-0.05
Free cash flow yield
-0.11-0.05-0.24-0.2-0.14
Debt to equity
0.571.160.090.090.06
Debt to assets
0.240.30.060.070.04
Net debt to EBITDA
-1.15-2.85-5.9536.1150.18
Current ratio
1.130.762.463.053.2
Interest coverage
-193.29-1.38-1.6500
Income quality
0.550.33-0.32.0210.36
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.720.27-1.180.90.59
Research and developement to revenue
0.090.06-0.030.110.07
Intangibles to total assets
0.10.1000
Capex to operating cash flow
0.140.130.030.020
Capex to revenue
-0.05-0.040.03-0.030
Capex to depreciation
-1.39-1.03-0.95-0.94-0.09
Stock based compensation to revenue
0.040.06-0.040.150.06
Graham number
1.821.66.542.11.38
ROIC
-0.17-0.20.72-0.07-0.06
Return on tangible assets
-0.15-0.230.47-0.06-0.03
Graham Net
-0.46-0.720.960.880.88
Working capital
4.18M-10.15M58.47M59.17M55.64M
Tangible asset value
25.38M11.48M78.46M74.28M70.78M
Net current asset value
-7.24M-21.13M55.04M55.98M52.62M
Invested capital
0.571.160.090.090.06
Average receivables
11.19M10.25M7.22M4.49M4.65M
Average payables
10.65M13.42M8.61M2.77M1.64M
Average inventory
15.76M15.51M11.61M7.77M7.7M
Days sales outstanding
59.8653.84-22.0148.2153.83
Days payables outstanding
78.7284.8763.5440.5827.4
Days of inventory on hand
93.8495.1141.1157.1162.16
Receivables turnover
1.51.67-4.091.871.67
Payables turnover
1.141.061.422.223.28
Inventory turnover
0.960.950.640.570.56
ROE
-0.32-0.780.73-0.09-0.04
Capex per share
-0.02-0.01-0.01-0.010

ENZ Frequently Asked Questions

What is Enzo Biochem, Inc. stock symbol ?

Enzo Biochem, Inc. is a US stock , located in New york of Ny and trading under the symbol ENZ

What is Enzo Biochem, Inc. stock quote today ?

Enzo Biochem, Inc. stock price is $1.27 today.

Is Enzo Biochem, Inc. stock public?

Yes, Enzo Biochem, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap